Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2007, Pages 469-475

  Xin, Hua Wen ^a   Wu, Xiao Chun ^a   Li, Qing ^a   Yu, Ai Rong ^a   Zhu, Min ^a   Shen, Yang ^a   Su, Dan ^a   Xiong, Lei ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Healthy volunteers; Pharmacokinetics; Schisandra sphenanthera extract; Tacrolimus

Indexed keywords

PLANT EXTRACT; SCHISANDRA SPHENANTHERA EXTRACT; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SCHISANDRA SPHENANTHERA; SCHISANDRACEAE; SINGLE DRUG DOSE; VOLUNTEER;

ADULT; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLANT EXTRACTS; SCHISANDRA; TACROLIMUS;

EID: 34548615016     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02922.x     Document Type: Article

References (29)

1. Pan Q, Wang T, Lu Q, Hu X, Schisandrin B. A novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 2005 335 : 406 11.
2. Sun M, Xu X, Lu Q, Pan Q, Hu X, Schisandrin B. A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 2007 246 : 300 7.
3. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 2006 72 : 824 37.
4. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004 32 : 1351 8.
5. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997 54 : 925 75.
6. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992 20 : 753 61.
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993 268 : 6077 80.
8. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997 62 : 41 9.
9. Hebert MF, Park JM, Chen YL, Akhtar S, Larson A. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004 44 : 89 94.
10. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001 41 : 289 97.
11. Bekersky I, Dressler D, Mekki Q. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001 41 : 176 82.
12. MacFarlane G, Scheller D, Ersfeld D, Jensen T, Jevans A, Wong PY, Kobayashi M. A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. Ther Drug Monit 1996 18 : 698 705.
13. Lee JW, Sukovaty RL, Farmen RH, Dressler DE, Alak A, Bekersky I. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. Ther Drug Monit 1997 19 : 201 7.
14. Dietemann J, Berthoux P, Gay-Montchamp JP, Batie M, Berthoux F. Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. Nephrol Dial Transplant 2001 16 : 2246 9.
15. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995 29 : 404 30.
16. Xu XJ, Liu GL, Deng YL, Miao HJ, Qin F, Zhang ZX, An DK. Pharmacokinetics of tacrolimus, a novel potent immunosuppressant in healthy Chinese volunteers. Chin J Antibiot 2002 27 : 59 62.
17. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997 27 : 201 14.
18. Cheung CY, Op den Builsch RA, Wong KM, Chan HW, Chau KF, Li CS, Leung KT, Kwan TH, de Vrie JE, Wijnen PA, van Dieijen-Visser MP, Bekers O. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 2006 7 : 563 74.
19. Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006 38 : 2850 2.
20. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999 39 : 91 6.
21. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Root SI. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003 18 : 819 22.
22. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000 67 : 451 7.
23. Bauer S, Stormer E, Kerb R, Johne A, Brockmoller J, Roots I. Differential effects of Saint John's wort (Hypericum perforatum) on the urinary excretion of D-glucaric acid and 6β-hydroxycortisol in healthy volunteers. Eur J Clin Pharmacol 2002 58 : 581 5.
24. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003 18 (Suppl. 1 i12 i15.
25. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005 61 : 567 72.
26. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Meth Find Exp Clin Pharmacol 2006 28 : 25 9.
27. Van Hooff JP, Boots JM, van Duijnhoven EM, Christiaans MH. Dosing and management guidelines for tacrolimus in renal transplant patients. Transpl Proc 1999 31 : 54S 57S.
28. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993 46 : 776 83.
29. Böttiger Y, Brattström C, Tyden G, Säwe J, Groth C. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999 48 : 445 8.